Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1
9 participants
INTERVENTIONAL
2019-12-03
2026-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Secondary objectives are to determine a recommended RP2D and schedule for further development of Karonudib, to determine the pharmacokinetics of Karonudib, to look for evidence of treatment efficacy. Overall survival will also be recorded.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* To determine the safety and tolerability of Karonudib in escalating doses for the treatment of patients with advanced relapsed/refractory Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL) , Diffuse Large B-Cell Lymphoma, Multiple Myeloma (MM) and high-risk Myelodysplastic Syndrome (MDS)AML, ALL, DLBCL, Burkitt´s lymphoma, multiple myeloma and high-risk MDS Primary Objective Part II
* To determine the safety and tolerability of Karonudib in combination with standard of care treatment, Idarubicinother anti-cancer agents for the treatment of patients with advanced progressive, relapsed/refractory AML, and high-risk MDS
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SEQUENTIAL
Extension part of the study - 20 patients with diagnosis of Relapsed, Refractory or Progressive AML and MDS to be enrolled and treated with RP2D.
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dose escalation
Karonudib is an oral inhibitor of MTH1 and will be supplied as an oral solution to be taken every other day. There are three planned dose cohorts. Patients will be given every second day dosing.
Karonudib
First part of the study - four different dose cohorts Extension part of the study - karonudib BID (twice a week) and Idarubicin days 1-3.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Karonudib
First part of the study - four different dose cohorts Extension part of the study - karonudib BID (twice a week) and Idarubicin days 1-3.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Age 18-75 years (may be extended to older if deemed fit).
3. The patient has received standard of care treatments and has refractory or relapsed or progressive disease with no suitable standard of care options available.
For expansion cohort (Cohort V): Patients can only have received a maximum of 70% of anthracycline lifetime exposure to date of proposed dosing day.
Cohorts I-IV: AML, ALL, DLBCL, Burkitt lymphoma, multiple myeloma or high-risk MDS, according to the WHO 2016 criteria.
4. Expansion cohort (Cohort V): Relapsed, Recurrent or Progressive AML or MDS according to the ELN 2017 criteriaWHO 2016 criteria.
5. For expansion cohort (Cohort V): Patients can only have received a maximum of 70% of anthracycline lifetime exposure to date of proposed dosing day.
6. The patient has received standard of care treatments and has refractory or relapsed disease with only experimental therapies as further treatment options.
7. Life expectancy of at least 8 weeks (as per investigators clinical assessment).
8. ECOG PFS 0-2
9. Patients must have measurable disease by blood or bone marrow or imaging examination.
10. Have a normal left ventricular ejection fraction (LVEF) based on institutional ranges.
11. Adequate hepatic and renal function defined as:
1. Total bilirubin \< 3 x ULN (does not apply to patients with Gilberts Syndrome).
2. AST and ALT ≤ 5 x ULN.
3. The calculated GFR is at least 30 ml/min using Cockcroft-Gault method.
12. Platelet count≥10 x 109/L. (Can be supported by platelet transfusion)
13. Subject must be able to take oral medication.
14. Negative pregnancy test according to CTFG guidance 2014 for females of child-producing potential.
Exclusion Criteria
2. Less than 4 weeks since stopping previous systemic chemotherapy treatment with the exception of stable dose Hydroxyurea, Trophosphamide, oral Cyclophosphamide, ImID or Thioguanine which needs to be stopped 10 x t1/2 prior to Karonudib administration.
3. Less than 1 week since stopping palliative radiotherapy.
4. Less than 2 weeks after surgery except access surgical procedures.
5. Less than 6 months since a clinically significant cardiovascular event such as myocardial infarction, unstable angina, angioplasty, bypass surgery, stroke or TIA.
6. Congestive heart failure NYHA class \> II.
7. History of arrhythmias or arrhythmias discovered during the screening period (apart from atrial fibrillation without ventricular tachycardia and premature extra beats).
8. Patients requiring anti-arrhythmic drugs except for stable dose beta-blocking or calcium channel blocking agents.
9. QTc interval \>470 ms at baseline (Fridericia correction).
10. Use of Fentanyl (must be stopped at least 1 week prior to initiation of Karonudib).
11. Use of anti-oxidants vitamins and Acetylcysteine (must be stopped within 48 hours of starting treatment with Karonudib).
12. Use of antidepressant medications which are substrate for CYP2D6 (must be stopped at least 3 weeks prior to starting treatment with Karonudib).
13. Any severe acute or chronic medical condition that places the patient at increased risk or interferes with the interpretation of study results.
14. Intracerebral engagement (patient with previously known engagement are eligible provided that there is no evidence of disease progression for a minimum of 8 weeks prior to inclusion.
15. Known acute or chronic infection with hepatitis B or C except for DNA-negative hepatitis B with stable dose anti-viral agents.
16. Known HIV infection.
17. Pregnant or breast-feeding women.
18. Patients with reproductive potential not implementing accepted and effective means of contraception.
19. Participation in any other clinical trial with a pharmaceutical product within 5 x t½, or minimum 1 week, since last dosing of the IMP, whichever is the shorter.
20. Acute promyelocytic leukemia (AML M3).
21. Uncontrolled ongoing systemic or localized infection.
22. Unable to comply with study procedures.
23. Peripheral neurological toxicity CTCAE grade 2 or higher.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Thomas Helleday Foundation
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Stefan Deneberg, MD
Role: PRINCIPAL_INVESTIGATOR
Karolinska University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Aarhus University Hospital
Aarhus, , Denmark
Rigshospitalet Copenhagen University Hospital
Copenhagen, , Denmark
University Clinical Center Belgrade
Belgrade, , Serbia
University Clinical Center Kragujevac
Kragujevac, , Serbia
Karolinska University Hospital
Huddinge, , Sweden
Örebro University Hospital
Örebro, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Hans Beier Ommen, MD
Role: primary
Claudia Schoellkopf, MD
Role: primary
Ana Vidović, MD
Role: primary
Danijela Jovanovic, MD
Role: primary
Stefan Deneberg, MD, PhD
Role: primary
Bertil Uggla, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MAATEO
Identifier Type: -
Identifier Source: org_study_id